2026 #NLASessions Accreditation Information

PROGRAM OVERVIEW:

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

Type of Activity
Live Activity
Application

Educational Objectives

At the end of this activity, all participants should be able to:

• Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

NLA Opening Session- TBD 

Session II- From Genetic Discovery to Clinical Action

• Explain the underlying rationale for targeting specific genes for sustained reduction of LDL-C and triglycerides
• Evaluate the cost effectiveness of cascade screening in FH 
• Review emerging therapeutic modalities that are derived from genetic targets  

W. Virgil Brown Distinguished Achievement Award and Lectureship

• Evaluate the management of patients with dyslipidemia

Session IV- Severe Hypertriglyceridemia: A Comprehensive Exploration of Uncommon Causes and Emerging Insights

• Recognize the clinical presentation and laboratory findings that should prompt consideration of GPIHBP1 autoantibody syndrome diagnosis
• Differentiate Familial Chylomicronemia Syndrome (FCS) from Multifactorial Chylomicronemia Syndrome (MCS) in patients with severe hypertriglyceridemia 
• Identify the pathognomonic physical markers of partial and generalized lipodystrophy and explain the underlying mechanism by which adipose tissue insufficiency drives severe hypertriglyceridemia 

Session V- Primary Prevention of ASCVD: A Joint Session from the European Atherosclerosis Society and the National Lipid Association

• Explain the clinical relevance of elevated levels of lipoprotein(a) [Lp(a)] in ASCVD risk stratification.
• Discuss guideline-directed approaches to patients with elevated levels of Lp (a)
• Discuss the role of imaging in enhancing risk assessment and early detection of ASCVD
• Review the rationale and evidence for combination lipid-lowering therapy in primary prevention based on recent guidelines.
• Identify barriers to implementing evidence-based prevention strategies in clinical practice.

Session VI- Rewriting the Rules for Primary Prevention: New Outcomes from Intensive LDL-C Reduction in High-Risk Patients 

• Apply data from landmark outcomes trials to treatment of high-risk ASCVD patients
• Recognize optimal lipid-lowering therapy required to achieve guideline-recommended LDL-C goals in high-risk ASCVD patients

Session VII – Abstract Award Winners

• Critically appraise emerging research and its applications to daily clinical practice 

Session VIII– Young Investigator Award Winners

• Critically appraise emerging research and its applications to daily clinical practice

Session IX- LSP Case Discussion

• Critically appraise emerging research and its applications to daily clinical practice

Session X- Managing the Child's Trajectory: Intervening on Early Cardiometabolic Risk

• Explain the underlying pathophysiology of insulin resistance progression in youth and identify strategies for the effective management of type 2 Diabetes Mellitus in pediatric populations  
• Describe the uses of imaging in early detection of atherosclerosis in youth 
• Evaluate the evidence supporting the long-term effectiveness of family-centered programs in improving pediatric metabolic health and reducing cardiovascular risk factors 

Session XI- Deciphering Women's Risk: New Perspectives on Lipids, Pre-eclampsia, and Navigating HRT in Cardiometabolic Health

• Identify dyslipidemia patterns associated with the risk of pre-eclampsia and its development in early pregnancy 
• Analyze the key data and expert rationale that informed the recent FDA decision to remove black box warnings on HRT products regarding cardiovascular disease
• Articulate the specific roles and responsibilities of an interdisciplinary team developing and implementing comprehensive care plans from pre-conception through postpartum for women with cardiovascular disease 

Session XII-Inflammation: The GI, Metabolic, and Renal Link

• Explain the dual pathological mechanisms by which elevated Lp(a) contributes ASCVD
• Discuss how non-invasive imaging can contribute to distinguishing steatosis from inflammation and advanced fibrosis in MASLD
• Explain how alterations in the gut microbiome can reduce inflammation and mitigate cardiorenal risk

 

 

 

2026 SCIENTIFIC SESSIONS:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.5 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 16.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 16.5 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

Pharmacist Accreditation Statement

Universal Activity Number Application UAN JA0007192-0000-26-001-L01-P (Application)

This Activity has been approved for 16.5 contact hour(s) (1.65 CEUs) of the Accreditation Council for Pharmacy Education

Nursing

The maximum number of hours awarded for this CE activity is 16.5 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

 

Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
 

For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
For Dietitians: Upon completion of the activity evaluation form, dietitians may submit evaluations of the quality of activities/materials to CDR. Poor evaluations of activities/materials may trigger an audit of the activities / materials by CDR.

 

Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.

 

Commercial Support:
Full notification of commercial support will be provided in the activity materials.